As manufacturers and stakeholders work to streamline patient access at therapy launch, a critical gap often persists in the sustained support patients require over time. In the fi ...

In today's Pharma Pulse, the FDA approves Icotyde as the first targeted oral peptide therapy for moderate-to-severe plaque ...

Jordan Armstrong, VP of Business Development at AssistRX, explains how companies can tailor direct-to-patient strategies into their commercialization plans. At this year’s Access USA conference, ...

Cold Chain Technologies (CCT) has announced the upcoming launch of MedAssure, a new cold chain orchestration platform. The platform will be officially introduced at LogiPharma 2026, where the company ...

Brok Vandersteen, VP of Business Development, AssistRX, explains how policy pressures push life sciences companies toward direct-to-patient model adoption. At this year’s Access USA conference, ...

In the second of his three-part Pharmaceutical Commerce interview, Jay Bregman discusses how rising demand for GLP-1 therapies is challenging employers to reassess how they manage ...

Brok Vandersteen, VP of Business Development, AssistRX, explains how policy pressures push life sciences companies toward direct-to-patient model adoption.

This insight piece explores how treatment patterns in bladder cancer have shifted as immunotherapy options have expanded in community oncology. You’ll learn how combination regimens such as enfortumab ...

In today’s Pharma Pulse, the FDA expands a key biologic approval for pediatric patients, and new research highlights the success of pharmacist-led testing in rural communities. Welcome to Pharma Pulse ...

In today's Pharma Pulse, ongoing conflict in the Middle East disrupts critical pharmaceutical cold chains, while AstraZeneca and partners launch a new program to decarbonize industrial heat across ...

A $3 billion China investment targets localized oral solid-dose manufacturing and supply-chain redundancy to support ...

Industrial process heat is a dominant Scope 1 driver in pharma manufacturing, with early Secaro data suggesting ~80% facility emissions are Scope 1 and ~60% from natural gas. Adoption of renewable ...